Overview

A Safety and Efficacy Study of Daikenchuto (TU-100) to Relieve Abdominal Bloating in Female Subjects With Irritable Bowel Syndrome

Status:
Completed

Trial end date:
2016-04-01

Target enrollment:

Participant gender:

Summary

The aim of this study is to assess the effect of orally administered TU-100 (5 g three times daily [TID]) as compared to placebo on abdominal bloating rating in female IBS patients.

Phase:

Phase 2

Details

Lead Sponsor:

Tsumura USA

Collaborator:

ICON Clinical Research